New combo therapy under observation for advanced colon cancer
NCT ID NCT07494578
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is observing 300 adults with metastatic colorectal cancer who are receiving a combination of two drugs (fluoropyrimidine and bevacizumab). The goal is to measure how long patients live and how long the cancer stays under control. The study is not testing a new treatment but gathering real-world data from 15 Italian centers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Policlinico Universitario Agostino Gemelli
Rome, Lazio, 00160, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can delivering cancer drug directly to the liver shrink tumors?
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a Two-Drug combo outsmart resistant colorectal cancer?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a Triple-Drug rechallenge tame colorectal cancer?